William P Clarke

List of Publications by Year
in descending order

68 papers	4,256 citations	168829 31 h-index	124990 64 g-index
69 all docs	69 docs citations	69 times ranked	4090 citing authors

#	Article	IF	Citations
1	Age-related changes in peripheral nociceptor function. Neuropharmacology, 2022, 216, 109187.	2.0	6
2	Longâ€term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox. Pharmacology Research and Perspectives, 2021, 9, e00887.	1.1	9
3	Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons. Neuropharmacology, 2019, 151, 208-218.	2.0	12
4	Peripheral Kappa Opioid Receptor (KOR)â€Mediated Antinociception Requires G Proteinâ€Gated Inward Rectifying Potassium (GIRK) Channels. FASEB Journal, 2019, 33, 808.18.	0.2	0
5	Methocinnamox (MCAM) is a Selective, Long Acting Antagonist at Mu Opioid Receptors In Vitro. FASEB Journal, 2019, 33, 498.8.	0.2	1
6	Allosterism within <i>Î´</i> Opioidâ€“<i>Îº</i> Opioid Receptor Heteromers in Peripheral Sensory Neurons: Regulation of <i>Îº</i> Opioid Agonist Efficacy. Molecular Pharmacology, 2018, 93, 376-386.	1.0	17
7	Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology, 2018, 21, 962-977.	1.0	102
8	Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. ELife, 2017, 6, .	2.8	36
9	Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 411-419.	1.3	12
10	Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 319-328.	1.3	11
11	Functional Selectivity of Kappa Opioid Receptor Agonists in Peripheral Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 174-182.	1.3	30
12	Dual Regulation of<i>Î´</i>-Opioid Receptor Function by Arachidonic Acid Metabolites in Rat Peripheral Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 44-51.	1.3	19
13	Atypical antipsychotics and inverse agonism at 5-HT₂ receptors. Current Pharmaceutical Design, 2015, 21, 3732-3738.	0.9	44
14	G protein-coupled Receptor 30 (GPR30) Forms a Plasma Membrane Complex with Membrane-associated Guanylate Kinases (MAGUKs) and Protein Kinase A-anchoring Protein 5 (AKAP5) That Constitutively Inhibits cAMP Production. Journal of Biological Chemistry, 2014, 289, 22117-22127.	1.6	53
15	Activation of Estrogen Receptor Î± Enhances Bradykinin Signaling in Peripheral Sensory Neurons of Female Rats. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 526-532.	1.3	16
16	Signalling profile differences: paliperidone versus risperidone. British Journal of Pharmacology, 2013, 170, 532-545.	2.7	24
17	Allosteric Interactions between Î´ and Îº Opioid Receptors in Peripheral Sensory Neurons. Molecular Pharmacology, 2012, 81, 264-272.	1.0	54
18	Metallopeptidase inhibition potentiates bradykinin-induced hyperalgesia. Pain, 2011, 152, 1548-1554.	2.0	15

#	Article	IF	Citations
19	Regulation of Îº-Opioid Receptor Signaling in Peripheral Sensory Neurons In Vitro and In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 92-99.	1.3	31
20	17Î²-Estradiol Rapidly Enhances Bradykinin Signaling in Primary Sensory Neurons In Vitro and In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 190-196.	1.3	24
21	Use of functional assays to detect and quantify functional selectivity. Drug Discovery Today: Technologies, 2010, 7, e31-e36.	4.0	8
22	Inverse Agonism at Serotonin and Cannabinoid Receptors. Progress in Molecular Biology and Translational Science, 2010, 91, 1-40.	0.9	16
23	Evidence for Distinct Antagonist-Revealed Functional States of 5-Hydroxytryptamine_{2A}Receptor Homodimers. Molecular Pharmacology, 2009, 75, 1380-1391.	1.0	60
24	Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. , 2009, 121, 160-173.		99
25	Rapid pain modulation with nuclear receptor ligands. Brain Research Reviews, 2009, 60, 114-124.	9.1	55
26	Peripheral delta opioid receptors require priming for functional competence in vivo. European Journal of Pharmacology, 2009, 602, 283-287.	1.7	52
27	Functional Selectivity at Serotonin Receptors. , 2009, , 155-176.		5
28	A Conservative, Single-Amino Acid Substitution in the Second Cytoplasmic Domain of the Human Serotonin_{2C}Receptor Alters Both Ligand-Dependent and -Independent Receptor Signaling. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 1084-1092.	1.3	48
29	Fine-tuning serotonin2c receptor function in the brain: Molecular and functional implications. Neuropharmacology, 2008, 55, 969-976.	2.0	85
30	Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression. Progress in Brain Research, 2008, 172, 287-305.	0.9	69
31	Rapid Modulation of Î¼-Opioid Receptor Signaling in Primary Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 839-847.	1.3	60
32	Integrins regulate opioid receptor signaling in trigeminal ganglion neurons. Neuroscience, 2007, 144, 889-897.	1.1	46
33	Functional Selectivity and Classical Concepts of Quantitative Pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1-13.	1.3	997
34	Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1054-1061.	1.3	105
35	Development of functionally selective agonists as novel therapeutic agents. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 421-428.	0.5	17
36	PAR-2 agonists activate trigeminal nociceptors and induce functional competence in the delta opioid receptor. Pain, 2006, 125, 114-124.	2.0	65

#	Article	IF	Citations
37	Modulation of bradykinin signaling by EP24.15 and EP24.16 in cultured trigeminal ganglia. Journal of Neurochemistry, 2006, 97, 13-21.	2.1	33
38	Differential Effects of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-Hydroxytryptamine2C Receptor-Mediated Responses. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 260-268.	1.3	37
39	Agonist-Directed Trafficking of 5-HT Receptor-Mediated Signal Transduction. , 2006, , 207-235.		3
40	What's for Lunch at the Conformational Cafeteria?. Molecular Pharmacology, 2005, 67, 1819-1821.	1.0	16
41	Bradykinin-Induced Functional Competence and Trafficking of the Â-Opioid Receptor in Trigeminal Nociceptors. Journal of Neuroscience, 2005, 25, 8825-8832.	1.7	148
42	Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends in Pharmacological Sciences, 2005, 26, 625-630.	4.0	98
43	Intracellular Ca2+Regulates Amphetamine-Induced Dopamine Efflux and Currents Mediated by the Human Dopamine Transporter. Molecular Pharmacology, 2004, 66, 137-143.	1.0	89
44	Constitutive Activity of the Serotonin2C Receptor Inhibits In Vivo Dopamine Release in the Rat Striatum and Nucleus Accumbens. Journal of Neuroscience, 2004, 24, 3235-3241.	1.7	297
45	5-HT2C constitutive receptor activity: effector pathway dependence. International Congress Series, 2003, 1249, 119-130.	0.2	1
46	Temporal Regulation of Agonist Efficacy at 5-Hydroxytryptamine (5-HT)1Aand 5-HT1BReceptors. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 200-205.	1.3	8
47	Rapid Desensitization of the Serotonin2C Receptor System: Effector Pathway and Agonist Dependence. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 957-962.	1.3	62
48	Nerve Growth Factor Amplifies Cyclic AMP Production in the HT4 Neuronal Cell Line. Journal of Neurochemistry, 2002, 64, 220-228.	2.1	12
49	Regulation of 5-HT1A and 5-HT1B receptor systems by phospholipid signaling cascades. Brain Research Bulletin, 2001, 56, 471-477.	1.4	19
50	RNA-editing of the 5-HT2C receptor alters agonist-receptor-effector coupling specificity. British Journal of Pharmacology, 2001, 134, 386-392.	2.7	130
51	Clarke and Bond reply. Trends in Pharmacological Sciences, 1999, 20, 7-8.	4.0	3
52	Pleiotropic Behavior of 5-HT2A and 5-HT2C Receptor Agonists. Annals of the New York Academy of Sciences, 1998, 861, 104-110.	1.8	66
53	Interactions between Effectors Linked to Serotonin Receptors. Annals of the New York Academy of Sciences, 1998, 861, 111-120.	1.8	31
54	The elusive nature of intrinsic efficacy. Trends in Pharmacological Sciences, 1998, 19, 270-276.	4.0	95

#	Article	IF	Citations
55	Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus. Molecular Pharmacology, 1998, 54, 94-104.	1.0	484
56	Prolactin Suppression Enhances the Effects of Perioperative Donor-Specific Blood Transfusions on Graft Survival. Journal of Surgical Research, 1996, 64, 190-197.	0.8	2
57	Synthesis of (+)-(R)- and (?)-(S)-trans-8-hydroxy-2-[N-n-propyl-N-(3?-iodo-2?-propenyl)] aminotetralin: New 5-HT1A receptor ligands. Chirality, 1995, 7, 452-458.	1.3	5
58	A potential 5-HT1A receptor antagonist: p-MPPI. Life Sciences, 1994, 55, 1459-1462.	2.0	59
59	Estrogen effects on 5-HT1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Research, 1990, 518, 287-291.	1.1	56
60	Estrogen enhances a 5-HT1A response in hippocampal slices from female rats. European Journal of Pharmacology, 1989, 160, 195-197.	1.7	23
61	Chronic estrogen effects on 5-hydroxytryptamine-mediated responses in hippocampal pyramidal cells of female rats. Neuroscience Letters, 1989, 106, 181-187.	1.0	29
62	Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate. Brain Research, 1987, 410, 357-361.	1.1	56
63	Effect of Lesions of the Corticomedial Amygdala on the Nocturnal Prolactin Surge. Neuroendocrinology, 1985, 41, 297-305.	1.2	7
64	The influence of blinding, olfactory bulbectomy and pinealectomy on plasma and anterior pituitary prolactin levels and on uterine and anterior pituitary weights in normal and neonatally androgenized rats. Life Sciences, 1985, 36, 1617-1624.	2.0	1
65	Spiperone differentiates multiple 5-hydroxytryptamine responses in rat hippocampal slices in vitro. European Journal of Pharmacology, 1985, 116, 195-197.	1.7	63
66	The Influence of Blinding, Olfactory Bulbectomy, and Pinealectomy on Twenty Four-Hour Plasma Prolactin Levels in Normal and Neonatally Androgenized Female Rats*. Endocrinology, 1984, 115, 1256-1261.	1.4	7
67	The influence of anesthetics on the estrogen-induced afternoon prolactin surge. Althesin does not block the surge. Life Sciences, 1981, 29, 277-284.	2.0	10
68	Electrical stimulation of rewarding hypothalamic sites in the 13-lined ground squirrel, Citellus tridecemlineatus, during hibernation: Sensitivity and thermogenic effects. Comparative Biochemistry and Physiology A, Comparative Physiology, 1981, 69, 479-486.	0.7	3